Upregulation of SKA3 and associated cancer progression have also been reported in other tumors, including lung adenocarcinoma [16], prostate cancer [17], breast cancer [18], glioma [19], kidney renal papillary cell carcinoma [13], skin cutaneous melanoma [20] and bladder cancer [21]. This evidence concerns the gene SKA3 and prostate carcinoma.